InvestorsHub Logo
Followers 78
Posts 10233
Boards Moderated 9
Alias Born 06/06/2017

Re: None

Tuesday, 03/10/2020 7:50:21 PM

Tuesday, March 10, 2020 7:50:21 PM

Post# of 3140
Onconova (ONTX) to Report Q4 Earnings: What's in Store?

Zacks Equity Research

Investors will focus on Onconova Therapeutics, Inc.’s ONTX lead candidate, rigosertib, which is a proprietary phase III small molecule, when it reports fourth-quarter 2019 results.

The company’s performance over the previous four quarters has been mixed. It beat earnings estimates in three, while missed in one of the trailing four quarters, with the average positive surprise being 11.48%. In the last reported quarter, Onconova delivered a positive surprise of 1.32%.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONTX News